<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989192</url>
  </required_header>
  <id_info>
    <org_study_id>21-0280</org_study_id>
    <nct_id>NCT04989192</nct_id>
  </id_info>
  <brief_title>Dose Efficiency of Modern CT Scanners in Oncologic Scans</brief_title>
  <official_title>On Dose Efficiency of Modern CT-Scanners in the Staging of Malignancies - a Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Augsburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Augsburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CT-Staging is crucial for therapy planning of patients with malignancies. Dose efficiency and&#xD;
      image quality are important parameters for these examinations. Up to now, scientific evidence&#xD;
      of dose efficiency of modern CT scanners is mostly derived from retrospective analyses. This&#xD;
      prospective study systematically analyzes dose efficiency and image quality of three modern&#xD;
      CT scanners by randomization of patients who are scheduled for a CT scan to examine the&#xD;
      status of malignancies. After giving informed consent and randomization (1:1:1), the CT scan&#xD;
      will be performed at one of the modern CT scanners available at our department. This will&#xD;
      allow a systematic allocation to the different scanners.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">August 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization of patients referred for a staging CT scan one of three CT scanners routinely used for this purpose in our department</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>no masking required</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Image Quality</measure>
    <time_frame>1 year</time_frame>
    <description>measured as signal, noise and modulation transfer function equivalent parameters derived from patient scans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiation Dose</measure>
    <time_frame>1 year</time_frame>
    <description>measured as x-ray tube parameters such as dose length product (DLP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Image Quality (entire cohort and for individual disease groups)</measure>
    <time_frame>1 year</time_frame>
    <description>measured by blinded evaluation by radiologists</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>CT scanner 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo imaging on scanner 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT scanner 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo imaging on scanner 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT scanner 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo imaging on scanner 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Scan at CT scanner 1</intervention_name>
    <description>Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar among all three arms.</description>
    <arm_group_label>CT scanner 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Scan at CT scanner 2</intervention_name>
    <description>Patients will undergo imaging on a modern 128 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.</description>
    <arm_group_label>CT scanner 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Scan at CT scanner 3</intervention_name>
    <description>Patients will undergo imaging on a modern 20 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.</description>
    <arm_group_label>CT scanner 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical suspicion of a malignancy or known / confirmed malignancy AND&#xD;
&#xD;
          -  indication for contrast-enhanced CT of the body confirmed by board-certified&#xD;
             radiologist ('justifying indication' according to German/European radiation protection&#xD;
             law) AND&#xD;
&#xD;
          -  patient (is able to give informed consent and) has given informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  known or suspected pregnancy&#xD;
&#xD;
          -  contraindications for contrast agent (renal failure, allergy, hyperthyroidism)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Schwarz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√§tsklinikum Augsburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florian Schwarz, MD</last_name>
    <phone>+498214002441</phone>
    <email>radiologie-studien@uk-augsburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Bavaria</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Schwarz, MD</last_name>
      <phone>+498214002441</phone>
      <email>radiologie-studien@uk-augsburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spectral CT</keyword>
  <keyword>CT</keyword>
  <keyword>Computed Tomography</keyword>
  <keyword>Radiation Dose</keyword>
  <keyword>Dose Efficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share individual participant data upon request (pending final approval by the data protection officer).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Requests for sharing individual participant data will be considered at the time of publication of the first manuscript containing result data.</ipd_time_frame>
    <ipd_access_criteria>We plan to share data on request at this point in time.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

